MENLO PARK, Calif. - Oruka Therapeutics, Inc. (NASDAQ:ORKA), a biotechnology company focused on chronic skin diseases, presented new preclinical data on its monoclonal antibody ORKA-001 at the European Academy of Dermatology and Venereology Congress. The data suggests that ORKA-001 has a significantly longer half-life in non-human primates (NHP) than the existing psoriasis treatment risankizumab.
ORKA-001, targeting IL-23p19, demonstrated a half-life of 30.3 days post subcutaneous administration and 33.8 days following intravenous administration. This extended half-life could potentially allow for dosing intervals of once every six months or even once yearly in humans, based on projections from the preclinical pharmacokinetics.
The company's CEO, Lawrence Klein, expressed confidence in ORKA-001's development trajectory, stating that the antibody's extended half-life and similar binding affinity to risankizumab show "tremendous potential" to improve the treatment regimen for patients with plaque psoriasis (PsO).
Oruka Therapeutics is aiming to improve the quality of life for patients with PsO by reducing the frequency of treatment dosages. Current IL-23p19 inhibitors, which are considered first-line therapy for moderate-to-severe PsO, require dosing four to six times per year and do not fully clear the skin in a significant portion of patients. ORKA-001, by contrast, is designed for less frequent administration and aims to achieve higher rates of disease clearance.
The announcement is based on findings from studies in non-human primates and other preclinical assays, which also indicated that ORKA-001 has a comparable functional potency for IL-23 antagonism in comparison with risankizumab.
Oruka Therapeutics is developing a proprietary portfolio of antibodies targeting core mechanisms underlying dermatologic and inflammatory diseases. The company's mission is to deliver high rates of complete disease clearance with minimal dosing frequency.
This article is based on a press release statement from Oruka Therapeutics. The forward-looking statements within the press release are subject to various risks, uncertainties, and assumptions. The actual future results for Oruka and ORKA-001 may differ materially from those projected in these statements.
In other recent news, Oruka Therapeutics has seen significant developments in its operations. The biotech company has secured $200 million in private investment in public equity (PIPE) financing, with participation from Braidwell LP and Venrock Healthcare Capital Partners. This funding is expected to sustain the company's operations through 2027. Additionally, ARCA biopharma's recent merger with Oruka Therapeutics has resulted in Oruka becoming a wholly-owned subsidiary of ARCA.
Oruka Therapeutics has also set clinical trial dates for its leading drug candidates, ORKA-001 and ORKA-002, designed to treat chronic skin diseases. The first human dosing for ORKA-001 is slated for the first quarter of 2025, with initial efficacy data in psoriasis patients expected in the latter half of 2026. ORKA-002 is expected to enter first-in-human trials in the third quarter of 2025.
Furthermore, Oruka Therapeutics received a Buy rating from TD Cowen, based on the company's advanced monoclonal antibody (mAb) engineering technology and the potential of its two leading drug candidates, ORKA-001 and ORKA-002. Jefferies also initiated coverage on Oruka Therapeutics with a Buy rating and set a price target of $40.00, based on the potential success of Oruka's two YTE modified "long-acting" enhanced antibodies. These are the recent developments in both the drug development and corporate aspects of Oruka Therapeutics.
InvestingPro Insights
As Oruka Therapeutics, Inc. (NASDAQ:ORKA) garners attention with its promising preclinical data on ORKA-001, investors are closely monitoring the company's financial health and market performance. According to real-time data from InvestingPro, Oruka Therapeutics has a market capitalization of $691.16 million. Despite the potential of ORKA-001, analysts provided by InvestingPro are cautious, noting that the company is not expected to turn a profit this year, which aligns with a P/E ratio currently standing at -3.94.
InvestingPro Tips highlight that Oruka Therapeutics has been struggling with weak gross profit margins, and the stock has experienced a significant downturn over the past month, with a one-month price total return of -17.19%. This downturn is consistent over various timeframes, from one week to one year, underscoring the challenges the company faces in the market.
Additionally, Oruka operates with a moderate level of debt, which could influence its financial strategies and investment potential moving forward. The company also does not offer dividends, which might be a consideration for income-focused investors. For those interested in exploring further, InvestingPro offers additional tips on Oruka Therapeutics, available at: https://www.investing.com/pro/ORKA
With the next earnings date scheduled for November 6, 2024, stakeholders will be keen to see how the company's strategic plans unfold. Meanwhile, the InvestingPro Fair Value estimate is currently set at $19.13, which is below the analyst target fair value of $40.5 but above the previous close price of $23.85, suggesting a nuanced perspective on the company's valuation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.